1162054-86-5

Basic information

• Product Name: (S)-1-methoxypropan-2-amine hydrochloride
• Synonyms: (S)-1-methoxypropan-2-amine hydrochloride;(S)-2-methoxy-1-methylethylamine hydrochloride;(S)-1-METHOXYPROPAN-2-AMINE HCL
• CAS NO: 1162054-86-5
• Molecular Formula: C₄H₁₁NO*ClH
• Molecular Weight: 125.59718
• EINECS: -0
• Mol File: 1162054-86-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-1-methoxypropan-2-amine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-methoxypropan-2-amine hydrochloride(1162054-86-5)
• EPA Substance Registry System: (S)-1-methoxypropan-2-amine hydrochloride(1162054-86-5)

Safety Data

• Hazardous Substances Data: 1162054-86-5(Hazardous Substances Data)

Usage

General Description

(S)-1-methoxypropan-2-amine hydrochloride, also known as methoxyphenamine hydrochloride, is a chemical compound with the molecular formula C4H12ClNO. It is a central nervous system stimulant and an amphetamine derivative. (S)-1-methoxypropan-2-amine hydrochloride has been used as a decongestant and bronchodilator in the treatment of respiratory conditions such as asthma and bronchitis. However, it has been found to have potential for abuse and has been regulated in some countries. The hydrochloride salt form of (S)-1-methoxypropan-2-amine is a crystalline solid that is soluble in water and ethanol. It is important for individuals to use this compound under the supervision of a healthcare professional and in accordance with regulations governing its use.

Upstream product

• 5878-19-3 Methoxyacetone 
• 194156-54-2 tert-butyl (S)-(1-methoxypropan-2-yl)carbamate 
• 955399-15-2 [(1R)-2-methoxy-1-methylethyl]carbamic acid tert-butyl ester 

Relevant articles and documents

SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

This application relates to substituted benzimidazoles of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application also relates to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasm, including tumors and/or cancers.

TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted pyrazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.